Qingyihuaji formula inhibits progress of liver metastases from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF

Integrative Cancer Therapies

Volumn 11, Issue 1, 2012, Pages 37-47

  Yin, Jian Hua ^a   Shi, Wei Dong ^a   Zhu, Xiao Yan ^a   Chen, Zhen ^a   Liu, Lu Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cyr61; liver metastasis; pancreatic cancer; Qingyihuaji formula (QYHJ); VEGF

Indexed keywords

CHINESE DRUG; CYSTEINE RICH PROTEIN 61; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; QINGYIHUAJI; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER WEIGHT; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WEIGHT CHANGE; WESTERN BLOTTING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BODY WEIGHT; CELL LINE, TUMOR; CYSTEINE-RICH PROTEIN 61; DISEASE PROGRESSION; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861813966     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735411400315     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 ; 58: 71-96
2. Smeenk HG, Incrocci L, Kazemier G, et al. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg. 2005 ; 22: 321-328
3. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst. 1995 ; 87: 1588-1592
4. Mattern J, Koomagi R, Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res. 1997 ; 17: 2249-2252
5. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000 ; 407: 242-248
6. Dupuy E, Hainaud P, Villemain A, et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol. 2003 ; 38: 793-802
7. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993 ; 24: 209-218
8. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation. 2002 ; 70: 561-573
9. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer. 1995 ; 62: 407-413
10. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000 ; 2: 737-744
11. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene. 2002 ; 21: 8178-8185
12. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004 ; 64: 1987-1996
13. Holloway SE, Beck AW, Girard L, et al. Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg. 2005 ; 200: 371-377
14. Tsai MS, Hornby AE, Lakins J, Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res. 2000 ; 60: 5603-5607
15. Chen N, Leu SJ, Todorovic V, Lam SC, Lau LF. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem. 2004 ; 279: 44166-44176
16. Lau LF, Nathans D. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J. 1985 ; 4: 3145-3151
17. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology. 2002 ; 143: 1441-1450
18. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1998 ; 95: 6355-6360
19. Liu L, Wu L, Lin S, Chou P, Xu Y. Therapeutic evaluation on advanced pancreatic cancer treated by integrative Chinese and western medicine: clinical analysis of 56 cases. Chin J Integr Med. 2004 ; (10). 236-237
20. Shen Y, Liu L, Chen Z, Meng Z, Song M. Study on Chinese medicine combined with chemotherapy for treatment of 32 cases of advanced pancreatic cancer. J Tradit Chin Med. 2006 ; (47). 115-117
21. Shen Y, Liu L, Shen J, Song M, Yu E. Impact of Qingyihuaji formula on proliferation and cell cycle of experimental pancreatic cancer in vivo. Chin J Basic Med Tradit Chin Med. 2006 ; (12). 97-99
22. Shen Y, Liu L, Meng Z, Chen Z, Ling J. Survival analysis on 64 cases of advanced pancreatic cancer treated by integrated Western and traditional Chinese medicine mainly with Qingyihuaji formula. J Tradit Chin Med. 2009 ; 50: 39-42
23. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995 ; 95: 1789-1797
24. Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol. 2002 ; 119: 122-124
25. Juuti A, Lundin J, Nordling S, Louhimo J, Haglund C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology. 2006 ; 71: 61-68
26. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001 ; 23: 291-299
27. Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer. 2003 ; 2: 12
28. Burris HR, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 ; 15: 2403-2413
29. Hiraoka T. Extended radical resection of cancer of the pancreas with intraoperative radiotherapy. Baillieres Clin Gastroenterol. 1990 ; 4: 985-993
30. Kyriazis AP, McCombs WR, Sandberg AA, Kyriazis AA, Sloane NH, Lepera R. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res. 1983 ; 43: 4393-4401
31. Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006 ; 26: 3579-3583
32. Chen J, Li C, Tian S. The expression of VEGF and MMP-2 in lung cancer and their roles in invasion and metastasis. China J Mod Med. 2004 ; 14: 98-99
33. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med. 2008 ; 86: 785-789
34. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009 ; 10: 992-1000